Avalo Therapeutics AVTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -88.8%— | -72.4%-22.4pp | -177.4%-133pp | —— | —— | |
| Return on assets | -71.1%-127pp | -58.6%-17.7pp | -89.4%-76.9pp | -39.4%+15.3pp | 55.7%+234pp | |
| Liquidity | ||||||
| Current ratio | 7.7×-14.9× | 8.1×-11.8× | 14.3×+12.9× | 12.4×+11.4× | 22.6×+22.1× | |
| Quick ratio | 7.7×-14.9× | 8.1×-11.8× | 14.3×+12.9× | 12.4×+11.4× | 22.6×+22.1× | |
| Cash ratio | 2.2×-20.1× | 1.2×-18.1× | 3.4×+2.1× | 4.6×+3.6× | 22.3×+21.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×-0.1× | 0×— | 0×— | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Interest coverage | -19.8×-8.2× | -16.8×+3.9× | -14.5×+15.4× | -13.6×— | -11.6×— | |
| Per Share | ||||||
| Book value per share | $3.40-70.9% | $6.20-65.1% | $6.54+235% | $9.66+643% | $11.66+109% | |
| Valuation | ||||||
| Market capitalization | $954.59M+1,783% | $329.31M+324% | $167.17M+81.4% | $53.6M+316% | $85.48M+390% | |
| Enterprise value | $929.6M-1,342% | $313.63M+660% | $140.46M+1,095% | $11.76M+115% | -$38.96M+57.2% | |
| Price / book | 13.8×+13.4× | 4×+3.4× | 1.8×-2.5× | 0.5×— | 0.7×— | |
| Earnings yield | -9%-154pp | -23.8%+21.4pp | -59.7%-51.1pp | -86.2%+195pp | 85.4%+905pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Avalo Therapeutics's profit margins?
- Avalo Therapeutics (AVTX) runs a 182.0% gross margin and a -15536.1% operating margin, with a -7965.8% net margin.
- Where do Avalo Therapeutics's ratios come from?
- Every ratio is computed from Avalo Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
